Fundraising FoxNavrogen
Philadelphia, US · Founded 2017 · Delaware corporation · 2 known investors
Find your way into Navrogen
59 people in our graph can introduce you to the Navrogen team.
Sign up to see every warm intro you have to Navrogen
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Navrogen team. We find them
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes you can't see from your own inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Navrogen is a biopharmaceutical company developing therapeutic agents that counter tumor-produced Humoral Immuno-Oncology (HIO) factors linked to suppressed humoral immunity and poor response to immune-mediated anti-cancer therapies. It uses proprietary screening, antibody engineering technologies, and diagnostic assays to identify patients whose tumors produce HIO factors, targeting cancer and immune-related disorders.
Founders & leadership
Navrogen was founded in 2017 by Nicholas Nicolaides and Luigi Grasso.
LG
Luigi GrassoCo-founder · Chief Scientific OfficerLuigi Grasso is co-founder and Chief Scientific Officer of Navrogen, a biopharmaceutical company developing therapeutic antibodies for cancer and immune-related disorders. He previously co-founded Morphotek in 2000, where he served as Chief Scientific Officer and led the development of multiple therapeutic antibody programs including MORAb-202, farletuzumab, amatuximab, and gimsilumab, and is a named inventor on over 60 patents.
SK
Steven KyriakosVP of Finance and OperationsSteven Kyriakos is VP of Finance and Operations at Navrogen. He has over two decades of finance and accounting experience in the biotech and pharmaceutical sectors, including founding and building the accounting, finance, and HR infrastructure for a biotech startup that was acquired by a global pharmaceutical company for $350M in 2007, and managing financial operations including SOX compliance, government grants, budgeting, and venture capital fundraising.
Investors · 2
Ben Franklin Technology PartnersreportedHarrisburg · $50K – $250K
How we know: funding news · Not right? Tell us
Also in the syndicate · 1
Ben Franklin Technology Partners of South Eastern Pennsylvanialead
Funding
SEC filings, press & company announcements$12.8M disclosed across 3 of 4 rounds · 2018–2024
- Undisclosed amountconvertible note financingSep 2019
Ben Franklin Technology Partners of South Eastern Pennsylvania (lead)
Source ↗
▶$542KraisedJun 2024 · 13 investors · BiotechnologyRule 506(b)
▶$542KraisedJun 2024 · 13 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Allan BedwickDirector
- Luigi GrassoExecutive Officer, Director
- Nicholas C. NicolaidesExecutive Officer, Director
- Leon O Moulder, JrDirector
- Offering amount
- $1M
- Amount sold
- $542K
- Minimum investment
- $5K
- Proceeds to insiders
- $542K
- First sale
- Jun 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$9.1MraisedFeb 2023 · 20 investors · BiotechnologyRule 506(b)
▶$9.1MraisedFeb 2023 · 20 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Nicholas C. NicolaidesExecutive Officer, Director
- Leon O. Moulder, Jr.Director
- Allan BedwickDirector
- Luigi GrassoExecutive Officer, Director
- Offering amount
- $9.3M
- Amount sold
- $9.1M
- First sale
- Jul 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$3.2MraisedSep 2019 · 18 investors · BiotechnologyRule 506(b)
▶$3.2MraisedSep 2019 · 18 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Nicholas NicolaidesExecutive Officer, Director
- Luigi GrassoExecutive Officer, Director
- Steven G KyriakosExecutive Officer
- Offering amount
- $3.2M
- Amount sold
- $3.2M
- Placement agents
- NA
- First sale
- Oct 2018
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 5
NephrogenNephrogen develops AI-powered AAV delivery vehicles for genetic medicines targeting kidney and pancreatic diseases. The company uses high-throughput in vivo screening to design tissue-specific viral vectors that are significantly more efficient and less immunogenic than existing alternatives.
BioworldBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
UrogenUroGen is a biotech company developing treatments for urothelial and specialty cancers using a proprietary sustained-release hydrogel platform technology. The company commercializes approved therapies for bladder and upper tract cancers, with additional candidates in development.
GeronGeron is a biopharmaceutical company focused on developing therapies for blood cancer. The company has over 30 years of experience in research and clinical development.
AnthrogenAnthrogen develops Odyssey, a family of protein language models with 102 billion parameters designed for multi-objective protein design. The models provide an API for researchers and organizations in biotechnology and drug discovery.
Companies working in the same space as Navrogen.
In the news
Frequently asked questions
- What does Navrogen do?
- Navrogen is a biopharmaceutical company developing therapeutic agents that counter tumor-produced Humoral Immuno-Oncology (HIO) factors linked to suppressed humoral immunity and poor response to immune-mediated anti-cancer therapies. It uses proprietary screening, antibody engineering technologies, and diagnostic assays to identify patients whose tumors produce HIO factors, targeting cancer and immune-related disorders.
- Who founded Navrogen?
- Navrogen was founded by Nicholas Nicolaides, Luigi Grasso in 2017.
- Who are Navrogen's investors?
- Navrogen's investors include Ben Franklin Technology Partners.
- How much funding has Navrogen raised?
- Navrogen has disclosed $12.8M raised across 3 of its 4 known rounds.
- Where is Navrogen headquartered?
- Navrogen is headquartered in Philadelphia, US.